The Future of Clinical Trials at the Neuro and Beyond
The Clinical Research Unit (CRU) manages clinical trials within The Neuro, the largest specialized neuroscience research and clinical centre in Canada. Under the direction of Dr. Angela Genge, the 2018 Forbes Norris award winner, the CRU’s 40 person team offers services in grant writing and trial development, trial recruitment and coordination, finance, ethics, biological sample processing, nursing, and medical writing. The CRU staff are dedicated to producing quality work, and committed to patient care and safety. Since 1992, the CRU has conducted over 300 trials, including all of the pivotal MS trials. The CRU has run every phase of industry sponsored clinical trials (I – IV), as well as investigator initiated clinical trials, bio-banking initiatives and patient registries.
During this webinar, Dr. Genge will discuss the CRU’s growing CNS- focused Phase 1 unit, building a national rare disease network, and pivotal trials that are recruiting at the CRU.
Registration is now available.
Speaker: Dr. Angela Genge, MD, FRCP(C)
Bio: Newfoundland-born, Dr. Angela Genge completed her medical degree at the Memorial University of Newfoundland. She completed her Canadian and American certifications in Internal Medicine and Neurology prior to completing a fellowship in neuromuscular diseases. She joined the staff of the Montreal Neurological Hospital in 1994 and became Director of the ALS Clinic in 1998.
Her involvement in clinical research began while still a resident in Neurology. She began assisting Dr. Gordon Francis, the founding director of the CRU at the Montreal Neurological Institute, in early trials in both multiple sclerosis and NeuroAIDS.
Although her interests in neurology focused on neuromuscular disease, she continued working with the CRU and brought in clinical trials in more neuromuscular disorders such as ALS, Myopathies, Neuropathies, Myasthenia Gravis and pain.
Dr. Genge was appointed Director of the CRU in 2004. Her goal is to expand both the number and scope of clinical trials in neurological disease.